Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review

[1]  A. Fendrick,et al.  The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA , 2022, PharmacoEconomics.

[2]  Jeroen J. van den Broek,et al.  The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs , 2022, Cancers.

[3]  Yi-Lin Chen,et al.  Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma , 2022, Frontiers in Oncology.

[4]  A. Bleckmann,et al.  Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach , 2022, Journal of Cancer Research and Clinical Oncology.

[5]  Youqing Wang,et al.  Supplementary Online Content , 2009 .

[6]  C. Tomasetti,et al.  Evaluating the impact of multicancer early detection testing on health and economic outcomes: Toward a decision modeling strategy , 2022, Cancer.

[7]  R. Vandermeer,et al.  The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer , 2022, Therapeutic advances in medical oncology.

[8]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. , 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  D. Husereau,et al.  Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients , 2021, Current oncology.

[10]  A. Hackshaw,et al.  Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK , 2021, British Journal of Cancer.

[11]  M. Kanda,et al.  Assessment of the Diagnostic Efficiency of a Liquid Biopsy Assay for Early Detection of Gastric Cancer , 2021, JAMA network open.

[12]  P. Gibbs,et al.  Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer , 2021, PharmacoEconomics.

[13]  James M. Cameron,et al.  Early economic evaluation to guide the development of a spectroscopic liquid biopsy for the detection of brain cancer , 2021, International Journal of Technology Assessment in Health Care.

[14]  A. Sonnenberg,et al.  Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach. , 2021, Gastrointestinal endoscopy.

[15]  S. Yip,et al.  Comprehensive Genomic Profiling for Non-Small-Cell Lung Cancer: Health and Budget Impact. , 2020, Current Oncology.

[16]  S. Yip,et al.  Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact. , 2020, Current oncology.

[17]  Y. Lotan,et al.  Impact of circulating microRNA test (miRNA‐371a‐3p) on appropriateness of treatment and cost outcomes in patients with Stage I non‐seminomatous germ cell tumours , 2020, BJU international.

[18]  M. Hartman,et al.  Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population , 2020, Gut.

[19]  H. Too,et al.  Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  Amy B. Knudsen,et al.  Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests , 2020, Journal of the National Cancer Institute.

[21]  D. Fernández-Lázaro,et al.  Clinical Perspective and Translational Oncology of Liquid Biopsy , 2020, Diagnostics.

[22]  S. Scudder,et al.  Budget Impact Analysis of EGFR Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece , 2020, Diagnostics.

[23]  Sarah Wordsworth,et al.  Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  D. Cescon,et al.  Circulating tumor DNA and liquid biopsy in oncology , 2020, Nature Cancer.

[25]  A. Pedraza,et al.  Analysis of the Cost-Effectiveness of Liquid Biopsy to Determine Treatment Change in Patients with Her2-Positive Advanced Breast Cancer in Colombia , 2020, ClinicoEconomics and outcomes research : CEOR.

[26]  The global challenge of cancer , 2020, Nature Cancer.

[27]  C. Martín-Saborido,et al.  Monitoring treatment response in metastasic colorectal cancer: Economic evaluation of PrediCTC versus computed tomography scan , 2019, Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish.

[28]  B. Kos-Kudła,et al.  NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease , 2019, Neuroendocrinology.

[29]  V. Vymetálková,et al.  Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review , 2018, International journal of molecular sciences.

[30]  Maarten J. IJzerman,et al.  Health economic impact of liquid biopsies in cancer management , 2018, Expert review of pharmacoeconomics & outcomes research.

[31]  J. Lindebjerg,et al.  Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma , 2018, Journal of experimental & clinical cancer research : CR.

[32]  Koen Degeling,et al.  Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models , 2017, BMC Medical Research Methodology.

[33]  Rom Langerak,et al.  Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  Hendrik Koffijberg,et al.  Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature , 2017, PharmacoEconomics.

[35]  A. Bardelli,et al.  Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.

[36]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[37]  Hendrik Koffijberg,et al.  A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models , 2017, Expert review of pharmacoeconomics & outcomes research.

[38]  N. Lawrentschuk,et al.  Prostate cancer screening with prostate-specific antigen: A guide to the guidelines , 2016, Prostate international.

[39]  P. Hofman,et al.  Pros: Can tissue biopsy be replaced by liquid biopsy? , 2016, Translational lung cancer research.

[40]  T. Wurdinger,et al.  Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer , 2015, Oncotarget.

[41]  A. Kalmár,et al.  Detection of Methylated Septin 9 in Tissue and Plasma of Colorectal Patients with Neoplasia and the Relationship to the Amount of Circulating Cell-Free DNA , 2014, PloS one.

[42]  Marius Ilie,et al.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? , 2014, Annals of translational medicine.

[43]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  K. Payne,et al.  Current methodological issues in the economic assessment of personalized medicine. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[45]  L. Garrison,et al.  Economic incentives for evidence generation: promoting an efficient path to personalized medicine. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[46]  U. Ladabaum,et al.  Colorectal Cancer Screening with Blood-Based Biomarkers: Cost-Effectiveness of Methylated Septin 9 DNA versus Current Strategies , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[47]  D. Owens,et al.  State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[48]  Claudio Franzetti,et al.  The Modelling Approach , 2010 .

[49]  Paul Ziprin,et al.  Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. , 2009, Surgical oncology.

[50]  Mark Nuijten,et al.  Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[51]  C. Thomas,et al.  Serum Tumor Markers: Past, State of the Art, and Future , 2001, The International journal of biological markers.

[52]  Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment. , 2020, Ontario health technology assessment series.

[53]  S. Sullivan,et al.  Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[54]  Maarten J. IJzerman,et al.  Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment? , 2013, PharmacoEconomics.

[55]  J. Hurteau.  Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer , 2007 .